The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1519
Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
The full article is available to subscribers Subscriber Login   

The FDA has approved dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully human monoclonal antibody, for treatment of adults with moderate to severe atopic dermatitis (eczema) that has not responded to topical therapies. It can be used with or without topical corticosteroids.

MECHANISM OF ACTION — Dupilumab binds to the IL-4 receptor alpha subunit shared by interleukin (IL)-4 and IL-13 receptors, inhibiting the signaling of these two cytokines, which are thought to be the drivers of atopic dermatitis, asthma, and possibly other allergic diseases.1

STANDARD TREATMENT — Application of moisturizers, emollients, and barrier creams can reduce the need for pharmacologic treatment of atopic dermatitis. Low-potency topical corticosteroids are generally used for treatment of mild atopic dermatitis that fails ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
Article code: 1519b
 Electronic, downloadable article - $25